Federal Regulation Impacting Medicare Drug Pricing Strategies for 2029

A federal regulation proposed for 2029 seeks to address pricing strategies for pharmaceuticals transitioning from intravenous to subcutaneous delivery methods. This initiative aligns with the government's ongoing negotiations with drug manufacturers concerning Medicare pricing, as mandated by the Inflation Reduction Act of 2022. The discussions focus on medications used by Medicare beneficiaries, primarily those over 65 or with disabilities, with the first price adjustments being recently implemented.

Among the drugs impacted are Opdivo and Keytruda, which accounted for $41 billion in global sales last year due to their widespread use in cancer treatment, significantly influencing Medicare expenditures. As their intravenous forms face expiration of patent protections by 2028, the market opens up to biosimilar alternatives. Merck and Bristol Myers' shift towards subcutaneous versions aims to prolong revenue streams while addressing infusion center capacity issues. While the proposed rule excludes these drugs from immediate price negotiations, expectations are high for their inclusion in the 2029 negotiation list announced by the Centers for Medicare & Medicaid Services (CMS) by February 1, 2027.

A notable regulatory consideration is the potential exclusion of drugs facing biosimilar or generic competition from the negotiation program. This could add uncertainty to the process, especially with expected biosimilar introductions for Opdivo and Keytruda by December 2028. Meanwhile, the Food and Drug Administration (FDA) plans to intensify audits and address review backlogs, emphasizing the importance of regulatory compliance in pharmaceutical advertising. In legislative circles, Sen. Chuck Grassley suggests revisiting pharmacy benefit manager business practices, foreshadowing significant Congressional action.